ProKidney Corp.
PROKHealthcareNASDAQBiotechnology · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 3
Part of the healthcare sector, ProKidney Corp. (PROK) is listed under Biotechnology. The company carries a $766.4M market cap, placing it firmly in the small-cap category. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Market Cap
$766.4M
Beta
1.72
P/E (TTM)
—
P/E (Fwd)
-3.27
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.59
ROE
-59.0%
ROA
-35.7%
Cash
$181.6M
Total Debt
$3.5M
Free CF
-$83.8M
52W Change
-15.1%
Annual Financials
Cash vs Debt
Where PROK stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PROK finished 3.80% above its 150-day moving average ($1.84) and 2.05% below its 200-day moving average ($1.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PROK overbought or oversold?
At the September 3, 2026 close, PROK's RSI(14) was 78.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $181.6M in cash comfortably exceeding the $3.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$83.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -59.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.72 means PROK is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PROK.